218 related articles for article (PubMed ID: 15738379)
41. Pulmonary fibrosis in a myeloma patient on bortezomib treatment. A new severe adverse effect of a new drug.
Duek A; Feldberg E; Haran M; Berrebi A
Am J Hematol; 2007 Jun; 82(6):502-3. PubMed ID: 17301973
[No Abstract] [Full Text] [Related]
42. Bortezomib in multiple myeloma.
Meisler AI
N Engl J Med; 2003 Sep; 349(13):1287-8; author reply 1287-8. PubMed ID: 14510013
[No Abstract] [Full Text] [Related]
43. Bortezomib-induced Sweet's syndrome.
Van Regenmortel N; Van de Voorde K; De Raeve H; Rombouts S; Van de Velde A; Lambert J; Schroyens W
Haematologica; 2005 Dec; 90(12 Suppl):ECR43. PubMed ID: 16464758
[TBL] [Abstract][Full Text] [Related]
44. Bortezomib.
Paramore A; Frantz S
Nat Rev Drug Discov; 2003 Aug; 2(8):611-2. PubMed ID: 12908468
[No Abstract] [Full Text] [Related]
45. Severe epidermal necrolysis after bortezomib treatment for multiple myeloma.
Fang B; Song Y; Ma J; Zhao RC
Acta Haematol; 2007; 118(2):65-7. PubMed ID: 17505132
[No Abstract] [Full Text] [Related]
46. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.
Bladé J; Cibeira MT; Rosiñol L
Acta Oncol; 2005; 44(5):440-8. PubMed ID: 16118077
[TBL] [Abstract][Full Text] [Related]
47. Severe pulmonary complications after bortezomib treatment in multiple myeloma.
Dun X; Yuan Z; Fu W; Zhang C; Hou J
Hematol Oncol; 2010 Mar; 28(1):49-52. PubMed ID: 19728395
[No Abstract] [Full Text] [Related]
48. Skin lesions induced by bortezomib.
Pour L; Hajek R; Zdenek A; Krejci M; Krivanova A; Vorlicek J
Haematologica; 2005 Dec; 90(12 Suppl):ECR44. PubMed ID: 16464759
[TBL] [Abstract][Full Text] [Related]
49. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
[TBL] [Abstract][Full Text] [Related]
50. Bortezomib-induced Sweet syndrome.
Knoops L; Jacquemain A; Tennstedt D; Theate I; Ferrant A; Van den Neste E
Br J Haematol; 2005 Oct; 131(2):142. PubMed ID: 16197442
[No Abstract] [Full Text] [Related]
51. Bortezomib.
Tariman JD; Lemoine C
Clin J Oncol Nurs; 2003; 7(6):687-9. PubMed ID: 14705489
[No Abstract] [Full Text] [Related]
52. Unexpected cardiotoxicity in haematological bortezomib treated patients.
Enrico O; Gabriele B; Nadia C; Sara G; Daniele V; Giulia C; Antonio S; Mario P
Br J Haematol; 2007 Aug; 138(3):396-7. PubMed ID: 17561972
[No Abstract] [Full Text] [Related]
53. Severe pulmonary complications after bortezomib treatment for multiple myeloma: an unrecognized pulmonary vasculitis?
Pitini V; Arrigo C; Altavilla G; Naro C
Leuk Res; 2007 Jul; 31(7):1027-8. PubMed ID: 17134751
[No Abstract] [Full Text] [Related]
54. Bortezomib increases survival of patients with relapsed multiple myeloma.
Health News; 2005 Sep; 11(9):9. PubMed ID: 16211682
[No Abstract] [Full Text] [Related]
55. Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity.
Lanzani F; Mattavelli L; Frigeni B; Rossini F; Cammarota S; Petrò D; Jann S; Cavaletti G
J Peripher Nerv Syst; 2008 Dec; 13(4):267-74. PubMed ID: 19192066
[TBL] [Abstract][Full Text] [Related]
56. Cutaneous lymphoid perivascular reaction with atypical CD30+ T cells in a patient with multiple myeloma treated with bortezomib.
Dehesa L; Bastida J; Limeres-González M; Campos-Adsuar C; Gómez-Duaso J
Clin Exp Dermatol; 2009 Dec; 34(8):e1031-2. PubMed ID: 20055832
[No Abstract] [Full Text] [Related]
57. [Very good partial response and long time to progression by short-term bortezomib plus dexamethasone therapy for a patient with relapsed and refractory multiple myeloma-a case report].
Fukushima T; Iwao H; Nakajima A; Miki M; Sakai T; Sawaki T; Tanaka M; Masaki Y; Hirose Y; Umehara H
Gan To Kagaku Ryoho; 2009 Aug; 36(8):1387-9. PubMed ID: 19692786
[TBL] [Abstract][Full Text] [Related]
58. Bortezomib-induced paralytic ileus is a potential gastrointestinal side effect of this first-in-class anticancer proteasome inhibitor.
Perfetti V; Palladini G; Brunetti L; Sgarella A; Brugnatelli S; Gobbi PG; Corazza GR
Eur J Gastroenterol Hepatol; 2007 Jul; 19(7):599-601. PubMed ID: 17556909
[TBL] [Abstract][Full Text] [Related]
59. Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma.
Richardson PG; Mitsiades C; Ghobrial I; Anderson K
Curr Opin Oncol; 2006 Nov; 18(6):598-608. PubMed ID: 16988581
[TBL] [Abstract][Full Text] [Related]
60. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy.
Kane RC; Farrell AT; Sridhara R; Pazdur R
Clin Cancer Res; 2006 May; 12(10):2955-60. PubMed ID: 16707588
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
